A study of HS-20093 for advanced stomach or gastroesophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, HS-20093, in people with advanced stomach or gastroesophageal junction cancer that has not responded to other treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with advanced or metastatic stomach or gastroesophageal junction cancer that has not responded to standard treatments.
- You are able to provide a tumor sample (either fresh or from a previous biopsy).
- You have at least one measurable tumor (by CT or MRI scan).
- You are willing to use effective birth control during the study.
- You have not been treated with a B7-H3 targeted drug or a topoisomerase I inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests a new drug combination (HS-20093) for people with advanced colorectal cancer that has spread or cannot be removed by surgery. It aims to see if the combination is safe and effective.
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
Hear when a new Advanced Gastric and Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.